Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020198534 - IMAGING AGENTS AND METHODS OF USING THE SAME

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS

1. A composition for internal imaging of a subject, comprising:

an imaging contrast agent; and

at least one carrier agent that can pass through cellular and tissue

membranes.

2. The composition of claim 1 , wherein the carrier agent comprises dimethyl sulfoxide, urea, or an alcohol.

3. The composition of claim 1 , further comprising a second carrier agent.

4. The composition of claim 1 , wherein the carrier agent comprises at least one of 1 -dodecylazacycloheptan-2-one, a 2-N-nonyl-1 ,3-dioxolane, an N-acetyl prolinate ester, an alkyldiloxane, transcarbam, iminosulfurane, a capsaicin derivative, a cinnamene compound, a terpene, a chitosan nanoparticle, dimethyl sulfoxide, a hyaluronic acid-transethosome, an alcohol, and urea.

5. The composition of claim 1 , wherein the imaging contrast agent comprises an iodine-based agent, a silver-based agent, or a barium-based agent.

6. The composition of claim 1 , wherein the imaging contrast agent is radiodense.

7. The composition of claim 1 , wherein the imaging contrast agent is perfusible.

8. The composition of claim 1 , wherein the imaging contrast agent is diffusible.

9. The composition of claim 1 , further comprising an enhancing agent.

10. The composition of claim 9, wherein the enhancing agent comprises a vasodilator or a vasoconstrictor.

11. The composition of claim 9, wherein the enhancing agent comprises

epinephrine or atropine.

12. The composition of claim 9, wherein the enhancing agent is at least one of N-acetyl aspartate, choline, epinephrine, norepinephrine, an opioid, creatine, myosin, a cholinesterase compound, an anti-cholinesterase compound, a paralytic agent, a peril uorocarbon (PFC) based oxygen carrier, a lactate, a beta blocker, an

antimicrobial, a calcium channel blocker, an antidepressant, an acetylcholinesterase inhibitor, a barbiturate, a non-opioid narcotic, a nonsteroidal anti-inflammatory agent, an enzyme, an enzyme inhibitor, or a target cell specific marker.

13. The composition of claim 1 , further comprising an odor-reducing agent.

14. The composition of claim 13, wherein the odor-reducing agent comprises vanilla extract, orange extract, citrus extract, urea, or an alcohol.

15. The composition of claim 1 , wherein the internal imaging comprises CT, X-ray, ultrasound, MRI, or photography.

16. The composition of claim 1 , wherein the subject is a plant, a fungus, or an animal.

17. The composition of claim 1 , wherein the subject is non-biologic.

18. A method for internally imaging a subject, comprising:

placing a first entry means into a chamber or region of the subject at or near one or more ends of the subject’s body;

ligating a section of the chamber or region downstream and/or upstream from the first entry means;

flushing fluid through a system of the subject being imaged to clear the contents of the system;

infusing the subject with a composition comprising an imaging contrast agent and a carrier agent that can pass through cellular and tissue membranes;

capping off the first entry means; and

scanning the subject.

19. The method of claim 18, wherein the first entry means comprises a catheter, trocar, cannula, or tube.

20. The method of claim 18, wherein a second entry means is placed at or near an opposite end of the subject’s body from the first entry means.

21. The method of claim 18, wherein the chamber comprises a blood vessel, a lymphatic vessel, respiratory airspace, cardiac space, or interstitial space.

22. The method of claim 18, wherein the fluid comprises an isotonic, a hypertonic, a hypotonic, and/or a preservative fluid.

23. The method of claim 18, further comprising flushing or perfusing the subject with a radiopaque, non-diffusible contrast agent prior to scanning.